Muscle disorders

Published on 12/04/2015 by admin

Filed under Neurology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2948 times

Chapter 10 Muscle disorders

Contents

Introduction

Muscle diseases include a number of rare, often progressive conditions leading to physical disability and, frequently, reduced life expectancy. Although each condition is rare, the overall prevalence of muscle disease is 1:1000 and individual disorders tend to present at around the same age, although there may be a wide range. Significant improvements in management means that affected children are surviving to middle age where previously they would have died and they are now presenting for care in adulthood (Wagner et al., 2007). Knowledge of these conditions tends to be poor outside the specialist area of paediatric physiotherapy. This chapter gives an overview of the most frequently seen disorders so the physiotherapist is aware of the different diagnoses which can influence overall management. For many conditions, management strategies are transferable and knowledge of the most frequently seen conditions will be relevant even to the most rare disorder. For a comprehensive text on muscle disorders the reader is referred to Dubowitz (1995).

Classification and diagnostic investigations

Since the 1980s tremendous advances in genetics and molecular biology have enhanced our understanding of the pathogenesis of muscle disorders. This has led to the availability of genetic testing for many conditions which has broadened our concept of classical phenotypes to include milder, even subclinical presentations. Becker muscular dystrophy (BMD) is a good example, whereby the disorder can result in loss of mobility as early as 16 years of age or as late as the sixth decade (Bradley et al., 1978), yet some patients present only with exertional cramps and myoglobinuria (Gospe et al., 1989). The limb girdle muscular dystrophies (LGMD) are another example. They are a heterogeneous group of disorders classified according to age of onset, inheritance pattern, and molecular and genetic defect, as shown in Table 10.1. The classification of congenital muscular dystrophies (CMD), based on clinical and/or pathological features, is also expanding and several forms are alleic with LGMD as shown in Table 10.2.

Table 10.1 Classification of the limb girdle and sex-linked muscular dystrophies in relation to the genetic defect

Type Gene Locus Gene Product
Autosomal dominant
LGMD1A 5q22-q34 Myotilin
LGMD1B 1q11-21 Lamin A/C
ADEDMD 1q11-21 Lamin A/C
LGMD1C 3p25 Caveolin 3
Autosomal recessive
LGMD2A 15q15.1-q21.1 Calpain 3
LGMD2B 2p13 Dysferlin
LGMD2C 13q12 γ Sarcoglycan
LGMD2D 17q21 α Sarcoglycan
LGMD2E 4q12 β Sarcoglycan
LGMD2F 5q33-q34 δ Sarcoglycan
LGMD2G 17q11-12 Telethonin
LGMD2H 9q31-34.1 Not yet known
LGMD2I 19q13.3 FKRP
LGMD2J 2q31 Titin
LGMD2K 9q34.1 POMT1
LGMD2L 11p13-p12  
LGMD2M 9q31 POMT2
Sex-linked
Dystrophinopathy Xp21 Dystrophin
(DMD, BMD)    
EDMD Xq28 Emerin

LGMD, limb girdle muscular dystrophy; ADEDMD, autosomal dominant Emery Dreifuss muscular dystrophy; DMD, Duchenne muscular dystrophy; BMD, Becker muscular dystrophy; EDMD, Emery Dreifuss muscular dystrophy.

Other conditions included within the diagnostic category of muscle disease are the congenital myopathies, myotonic disorders, spinal muscular atrophies (SMA), and mitochondrial and metabolic myopathies, as well as disorders affecting the neuromuscular junction, which can be inherited or acquired. Despite many advances in the field, a definitive diagnosis will still be lacking for some individuals other than the finding of clinical and pathological features of a myopathy.

Acquired neuromuscular disorders are more common in adults than children. Polymyositis and dermatomyositis are inflammatory conditions presenting with weakness and pain. The onset is either acute or subacute and may be precipitated by infections in children or malignancy in adults. Myasthenia gravis is an autoimmune disorder presenting in adults or older children, frequently associated with a thymoma (a benign enlargement of the thymus); there may be a history of diplopia (double vision), ptosis (droopy eyelids), bulbar symptoms and weakness precipitated by repetitive tasks. In adults, endocrine disorders, especially hypothyroidism, can present as a myopathy.

The history will most often elicit functional difficulites such as frequent tripping or legs giving way and difficulty climbing stairs. Examination may reveal muscle hypertrophy or wasting or a combination of both and nearly always muscle weakness involving facial, axial, proximal, distal or global muscles, depending on the disorder. Some disorders, such as Emery Dreifuss muscular dystrophy (EDMD), present with disproportionately severe joint contractures. Exercise-induced myalgia (muscle pain) is more likely to be the presenting complaint of a metabolic or mitochondrial myopathy, although it can be a feature of BMD. The development of a systemic complication, such as early-onset cataracts or cardiac rhythm disorder, can be the presenting feature of a muscle disorder such as myotonic dystrophy.

The severity of respiratory muscle involvement does not always correlate with the severity of skeletal weakness and it is, therefore, essential that all patients with neuromuscular disorders are monitored regularly for forced vial capacity (FVC) (Griggs et al., 1981; Hough, 1991; also see Ch. 15). Symptoms of incipient respiratory failure include recurrent chest infections, weight loss, early-morning headaches, sweating, disturbed nights and daytime somnolence. A sleep study will confirm nocturnal hypoventilation, and non-invasive respiratory support improves symptoms and can be life saving.

Diagnostic investigations include the serum concentration of creatine kinase (CK), which is raised in many muscle diseases, although a normal result does not exclude a muscle disorder. Where appropriate, biochemical analysis for metabolic disorders will include lactate, carnitine and acyl carnitine levels together with functional exercise testing. Electromyography (EMG) and nerve conduction studies may be useful in some cases, but this is by no means universal. Muscle biopsy is the definitive diagnostic test for most of the muscular dystrophies and myopathies. However, in some instances, such as spinal muscular atrophy and facioscapulohumeral muscular dystrophy, a blood test for DNA analysis is sufficient to confirm a diagnosis.

The muscular dystrophies

The muscular dystrophies are a heterogeneous group of genetically determined disorders associated with progressive degeneration of skeletal muscle. They can be subdivided into a number of different conditions based upon the mode of inheritance, protein, enzyme and/or genetic defect (Tables 10.1). The Xp21 dystrophies or dystrophinopathies are allelic disorders with a wide spectrum of severity with DMD at the most severe end, a group of intermediate patients and BMD at the milder end of the spectrum. X-linked cardiomyopathy (XLDC) is caused by a deletion in the same gene and results in a severe life-limiting cardiomyopathy, but little, if any, muscle weakness. All of these disorders are caused by a defect of the protein dystrophin and are characterized by X-linked inheritance, in which males are affected and females are carriers, although up to 10% of carriers can manifest muscle weakness. Apart from muscle hypertrophy particularly affecting the calf muscles, there is a normal appearance in infancy, although the serum, CK is very high. With advancing age there is progressive muscle weakness and wasting leading to severe physical disability.

Duchenne muscular dystrophy

DMD was first described by Meryon in 1852 and later by Duchenne. It is rapidly progressive and is the most severe of all the muscular dystrophies. The incidence is 1:3500 live male births and there is a prevalence in the population of 1.9–4.8 per 100 000 (Emery, 1991).

Clinical and diagnostic features

Children with DMD almost always have delayed motor milestones and about one-third of patients will also have learning difficulties leading to global developmental delay. The child often walks after 18 months of age, and when he does begin to walk he may be clumsy, and rarely acquires the ability to run or jump. If there is no family history the diagnosis may not be suspected until muscle weakness is obvious, usually by 5 years of age.

Progressive hip and knee extensor weakness causes difficulty in getting up from the floor resulting in a typical Gowers’ manouevre, whereby the child must give some assistance to hip and knee extension by pushing off from the thigh with the hand or forearm. With increasing weakness, the child climbs up his legs using both arms. An abnormal ‘waddling’ gait occurs because of early weakness of the hip abductors resulting in an inability to maintain a level pelvis when lifting one leg off the ground. The child inclines the trunk towards the stance leg to bring the centre of gravity of the body over that leg, and as he moves forward this action is continually repeated and accounts for the Trendelenburg sign. This is accompanied by widening of the base of support for increased stability, which contributes to the evolution of hip abduction contractures (iliotibial band tightness).

By 7–8 years of age, contractures of heel cords and ilio-tibial bands lead to toe walking. Without corticosteroid treatment ambulation is always lost by the 13th birthday and the mean age for loss of ambulation is 9.5 years (Emery & Muntoni, 2003). Prolonged sitting caused by wheelchair dependence leads to the rapid development of flexion contractures of the elbows, hips and knees.

In the early ambulatory phase of DMD, an equinus foot posture is precipitated by relative weakness of the ankle dorsiflexors compared with the better preserved plantar-flexors. Gait analysis has shown that a dynamic equinus is a necessary biomechanical adaptation to maintain knee stability in the presence of gross quadriceps muscle weakness. Forceful action of the ankle plantarflexors provides a torque which opposes knee flexion (Khodadadeh et al., 1986). Thus, contracture of the Achilles tendon, which eventually accompanies disease progression, is secondary to dynamic equinus.

Muscle involvement is bilateral and symmetrical and the proximal muscles are more affected than the distal groups. As the condition progresses the tendon reflexes become depressed and are eventually lost. In the ambulatory stage, the pelvic girdle is slightly more affected than the shoulder girdle. There is more severe weakness in the extensor groups than in the flexors, although this differential muscle involvement becomes less clear as the disease progresses, so that ultimately such patterns of weakness are no longer obvious. Finally, contractures become fixed and a progressive scoliosis develops. Scoliosis exacerbates existing respiratory muscle weakness, and in severe cases may render the child bed-bound if it is not managed with spinal fusion.

Muscle imbalance (caused by the specific pattern of developing weakness) and postural malalignment (resulting from compensatory adjustments to maintain standing equilibrium) are factors precipitating the eventual development of contractures about weight-bearing joints. These are relatively mild while the child remains ambulant but progress rapidly once there is dependence on a wheelchair. These postures combine lumbar lordosis, hip flexion and abduction, and ankle equinus. The first alteration of body alignment in DMD is a lumbar lordosis due to early weakness of the hip extensors, so that active stabilization of the hip joint is compromised. In order to maintain the line of force behind the hip joint and prevent collapse into hip flexion, there is an initial posterior alignment of the upper trunk resulting in a compensatory lumbar lordosis. As weakness progresses this is accompanied by an exaggerated anterior tilt of the pelvis which predisposes to contractures of the hip flexors. By 18 years of age cardiomyopathy and respiratory insufficiency are the norm.

Thus, DMD is a severe life-limiting disease characterized by muscle weakness, contracture, deformity and progressive disability. However, ‘incurable’ is not synonymous with ‘untreatable’. A variety of therapeutic and surgical measures are available that can help to minimize deformity, prolong independent ambulation and maximize functional capabilities. There is evidence that improved management strategies are resulting in increased survival rates (Eagle et al., 2002; Eagle et al., 2007). Corticosteroid treatment results in an increase in muscle strength followed by a slowing down of the dystrophic process (Manzur et al., 2008a). Most boys will die from respiratory or cardiac failure, but the introduction of nocturnal nasal ventilation has improved survival figures, such that the average life expectancy is now 25 years or more with non-invasive ventilation, compared with 19 years without this treatment (Eagle et al., 2002). The principles of successful management are based on an understanding of the natural evolution of patterns of weakness, contracture and deformity, so that intervention can be staged appropriately.

Pathology

Weakness in DMD results from the gradual loss of functional muscle fibres which are replaced by fat and connective tissue due to a lack of dystrophin, a protein encoded by the Xp21 gene, is the primary biochemical defect (Muntoni et al., 2003). Dystrophin is integral within a complex of proteins which stabilizes the integrity of the sarcolemmal membrane, particularly during the stress associated with repeated cycles of contraction and relaxation. Absence of dystrophin in the skeletal and cardiac muscle results in a reduction in permeability of the muscle cell membrane, so allowing excessive quantities of calcium to accumulate within the muscle fibre leading to myofibrillar over-contracture, breakdown of myofibrils and various metabolic disturbances that culminate in muscle fibre degeneration. Dystrophin isoforms are also expressed in Schwann and Purkinge cells found in the brain which is the reason for the high incidence of learning difficulty.

Diagnosis

Diagnosis is suspected by finding a raised serum creatine kinase usually in the region of 50–100 times the normal level. A muscle biopsy is necessary to confirm the diagnosis together with DNA analysis. Muscle biopsy can be undertaken as a percutaneous technique using a biopsy needle or as an open procedure, depending on the practice of the investigating unit. Muscle histology demonstrates dystrophic features which include: an increased variation of fibre size, evidence of necrosis with phagocytosis, an increase in central nuclei, hypercontracted eosinophillic hyaline fibres, and an increase in fat and connective tissue (Figure 10.1). Histochemical staining using antibodies to N, C and rod domain epitopes of dystrophin usually show complete absence of the protein, except for occasional revertent fibres (these are fibres which label normally with antibodies to dystrophin; their origin is not understood).

Weak or uneven labeling of dystrophin may be seen in BMD and intermediate phenotypes and thus can guide on prognosis. In manifesting carriers, dystrophin immunolabelling demonstrates a mosaic appearance with positive and negative fibres. Immunolabelling with other antibodies in both DMD and BMD shows a reduction of membrane proteins associated with dystrophin, and over expression of utrophin, a protein similar in structure to dystrophin.

DNA testing from a blood sample will demonstrate a frame-shift deletion within the dystrophin gene in approximately 60% of DMD patients, the rest will result from duplications and nonsense mutations (Mastaglia & Laing, 1996). Confirmation of the diagnosis by DNA testing allows carrier detection and prenatal diagnosis in the affected boy’s mother and female relatives. In some cases DNA analysis is the only test required to confirm the diagnosis of DMD. In BMD the reading frame of the gene is preserved (in-frame). Exceptions to the frame-shift rule occur with some deletions and thus a muscle biopsy is recommended to confirm the diagnosis.

General management

Informing parents that their child has DMD causes extreme distress and should only be undertaken by the most senior member of the team, in an appropriate environment, with a support worker present who can maintain contact with the family once they have left the hospital. The information given to the parents must be factual and honest, but delivered with sensitivity and empathy.

The long-term care of the child will require a specialist multidisciplinary team (MDT) liaising closely with community medical, educational and social agencies. As soon as the diagnosis is confirmed the child should have a MDT developmental assessment to screen for learning difficulty so that plans can be made for appropriate educational support. Social services will be required to become involved to ensure the family receives the correct State financial entitlements and will be paramount in arranging home adaptations, which are usually necessary by the time the child is 7 or 8 years of age, when the child has difficulty climbing stairs.

From an early age, tightness and subsequently contractures of the tendo-achilles (TA) develop. Daily passive stretching of the TA and provision of night splints are recommended as soon as any tightening is demonstrated. Later on, when significant pelvic girdle weakness is manifest by a waddling gait, the ilio-tibial bands and hip flexors may start to tighten. Care must be taken to ensure assessment at each outpatient visit with advice to undertake stretching exercises. The priority of physical management is to prolong ambulation for as long as possible, since once ambulation is lost scoliosis and joint contractures develop rapidly. At the point of loss of ambulation, light weight knee-ankle-foot orthoses (KAFOs) can be used to prolong walking (Figure 10.2). This usually involves a minor surgical procedure to percutaneously release any lower limb contractures, usually the TAs, together with an intensive rehabilitation programme. Where there are only moderate contractures of the TAs, serial casting may be an alternative to surgery to allow fitting of the KAFOs (Main et al., 2007). The parents and child must be both strongly motivated and well supported for this form of rehabilitation to be successful.

In recent years, there is growing evidence that treatment with corticosteroids (prednisolone or deflazacort) will stabilize muscle function for some time, therefore delaying the loss of ambulation by up to 2 years (Manzur et al., 2008a). Careful monitoring for side-effects is essential, especially weight gain, which may potentially have a negative effect on function. The potential benefit of longer-term steroid treatment has yet to be evaluated, but some open studies suggest preserved respiratory and cardiac function (Manzur et al., 2008a). Premature loss of ambulation can follow lower limb fractures or ligament strains unless active management, such as internal fixation, is instigated to promote early mobility. Immobilizing any joint beyond the initial painful phase should be actively discouraged.

Once independent ambulation is lost, regular use of a standing frame is recommended to maintain good posture and reduce contracture development. Rigid ankle foot orthoses (AFOs) are recommended for daytime use to maintain a good foot position. Likewise it is essential to ensure that the wheelchair provides good back and neck support (Pope, 2002) and, ideally, the controls of an electric wheel chair should be centrally placed. Swimming and hydrotherapy are particularly useful and enjoyed by the boys who find they can move more easily in the water.

A rapidly progressive scoliosis requiring surgical stabilization will develop in up to 95% of boys. There is, however, a reduced incidence and severity of scoliosis in glucocorticosteroid-treated boys (Biggar et al., 2006) which is likely to be due to prolongation of walking and increase in trunk muscle strength. Posterior spinal fusion is highly successful in correcting the deformity, and in improving posture and the quality of life for both patient and carer (Mehdian et al., 1989). The timing of operation is crucial since a decline in vital capacity occurs at the same time as the development of scoliosis. To avoid undue anaesthetic risks the procedure must be undertaken when the vital capacity is greater than 30% of predicted height (Manzur et al., 2008b). Thus surgical correction is usually recommended when the degree of spinal curvature is still relatively mild.

Management of restricted participation

Restricted participation has replaced the term ‘handicap’ in the revised International Classification of Functioning, Disability and Health by the World Health Organization (WHO ICF, 2001; see Ch. 11) and its management must take into account psychosocial issues, mobility and education. Providing an electric wheelchair is essential to providing a degree of independence, but this requires appropriate home adaptations including: widened doors and indoor/outdoor wheelchair access. A hoist is required for lifting in and out of the wheelchair, and the child will require a ground floor bedroom and bathroom with shower and adapted toilet. An electric bed enables the child to alter his position and saves the parents many sleepless nights. An adapted motor vehicle is required for transport to enable the child to drive his own wheelchair in and out of the vehicle.

The revolution in computer technology and its application to assistive devices has transformed the lives of many disabled people, e.g. the POSSUM system (Patient Operator Selector Mechanisms) enables the child to open and close doors, windows, curtains and turn on and off lights, etc. Access to the internet allows friendships to develop and provides a source of information and various services. Electronic games enable the boys to play competitively alongside their able-bodied companions and probably have a major effect on building self-esteem and reducing boredom.

Respiratory problems

With advancing age, respiratory impairment becomes inevitable and, if not recognized early, is an important cause of unpleasant symptoms or death. Characteristically there is a restrictive defect, with a reduction in total lung capacity caused by a combination of diaphragmatic and intercostal muscle weakness. Chest wall stiffness, recurrent aspiration and an inability to cough effectively compound the respiratory insufficiency leading to an increased frequency of chest infections (Smith et al., 1991). The forced vital capacity is a reliable measure of respiratory function, provided the boy is able to undertake a good technique (in some boys with learning difficulty this may be a problem) (Griggs et al., 1981). The forced vital capacity, when corrected for height, plateaus and then falls progressively on average between 12 and 14 years of age. Once the vital capacity falls below 1 L, in a boy who has reached skeletal maturity, the average life expectancy without treatment is 3 years (Phillips et al., 2001).

Sleep-related respiratory abnormalities play a major role in ventilatory failure, resulting in symptoms of hypercapnia which include: early-morning headache, nausea and sweating, daytime somnolence and a loss of respiratory drive (resulting in rapid deterioration into coma if a high concentration of oxygen is administered). Chronic nocturnal hypoxaemia leads to cor pulmonale (right heart failure), the ECG may show evidence of pulmonary hypertension and right heart strain (Carroll et al., 1991). Once the vital capacity falls below 40% sleep studies should be undertaken at regular intervals to monitor for nocturnal hypoventilation. Treatment by non-invasive nasal ventilation is effective in alleviating symptoms and prolongs survival (Eagle et al., 2002; Jeppesen et al., 2003; Simonds, 2000). There is recent evidence that the cumulative effect of both spinal surgery and nocturnal ventilation further improves survival (Eagle et al., 2007).

Cardiac problems

Post-mortem studies show that all boys with DMD have evidence of cardiomyopathy by 18 years of age. In practice, however, symptomatic cardiomyopathy is less common than might be expected. It has been assumed the sedentary lifestyle of these boys contributes to the lack of symptoms (Hunsaker et al., 1982). Abnormalities of the electrocardiogram are evident from an early age and will be present in all boys by 18 years of age (Nigro et al., 1990); the most common abnormality is a resting tachycardia, which is almost universal. Cardiac arrhythmias occur and may be a cause of early sudden death. When congestive cardiac failure does occur the progression is rapid and relentless. Monitoring with cardiac echo is recommended once ambulation is lost. Early treatment with ACE (angiotensin-converting enzyme) inhibitors has been shown to be beneficial, although the results need to be confirmed (Duboc et al., 2007).

Becker muscular dystrophy

Becker muscular dystrophy (BMD) is allelic to DMD, but has a milder phenotype (see Table 10.1) and has a prevalence of 1 in 30 000. It is caused by a partial deficiency of the protein dystrophin (Karpati et al., 2001).

General management

The management of BMD involves prevention of contractures and prolonging ambulation as with DMD. An active approach to management using low-intensity aerobic exercise has been shown to safely improve fitness and strength in individuals with mild BMD (Sveen et al., 2008). Home adaptations are essential in promoting independence and the patient may require support to continue working in an adapted environment. For those patients who are wheelchair dependent, regular standing, and preventing excessive weight gain and constipation are important. Prevention of respiratory infections by vaccination against influenza and pneumococcus, together with prompt antibiotic treatment of infection are important. Monitoring of respiratory function and overnight oximetry for sleep hypoxaemia are necessary. Symptoms of chronic ventilatory failure should be managed with non-invasive ventilation as for the DMD group. Regular cardiac monitoring with yearly ECGs and cardiac ECHOs every 2 or 3 years is necessary. Early intervention with ACE inhibitors for ventricular dysfunction may be helpful, but as yet has to be fully evaluated. If cardiac symptoms fail to respond to medical treatment, assessment for cardiac transplantation is warranted (Quinlivan & Dubowitz, 1992).

Emery–Dreifuss muscular dystrophy

This is a rare but clinically distinct form of MD. Two modes of inheritance exist. Firstly, a sex-linked form (EDMD) in which mutations in the Emerin gene located at Xq28 lead to a complete absence of the nuclear envelope protein Emerin (Mastaglia & Laing, 1996). Secondly, there is an autosomal dominant form (ADEDMD) in which the defective gene is at 1q11-q23 encoding for another nuclear envelope protein; Lamin A/C (LMNA) (Bonne et al., 1999).

Limb girdle muscular dystrophy

The limb girdle muscular dystrophies (LGMDs) are a clinically and genetically diverse group of disorders, characterized by the predominance of limb girdle weakness, with or without contractures (Table 10.1). Inheritance can be either dominant or recessive, depending upon the specific disorder. Clinical heterogeneity also occurs within some of these disorders, for example LGMD2B is caused by mutations in the dysferlin gene on chromosome 2p13 and is allelic to Miyoshi distal myopathy (Illarioshkin et al., 1997).

The onset of LGMD can occur at any time between childhood and old age, although the average age of onset is in the second and third decades. The disorders are progressive, with weakness usually affecting the shoulder girdle and pelvic girdle. Many patients will lose independent ambulation within 10–20 years of onset. The CK is frequently greatly increased and a combination of muscle biopsy and DNA analysis will often lead to a precise diagnosis.

Dilated cardiomyopathy is a relatively frequent complication of the LGMDs: routine ECG and, where appropriate, echocardiogram (ECHO) are recommended. In autosomal dominant Emery Dreifuss muscular dystrophy (ADEDMD, allelic to LGMD1B), cardiac conduction block requiring a defibrillator pacemaker is almost universal by the third decade and can be life-saving. Respiratory failure from diaphragmatic weakness, leading to sleep hypoventilation syndrome, occurs in most of the muscular dystrophies and must be screened for regularly. Generally, if the FVC is less than 50% of that expected for height, or if there is a greater than 20% drop in FVC when the patient lies flat, sleep hypoventilation should be suspected and a sleep study should be arranged. Treatment with non-invasive mask ventilation is highly effective in alleviating symptoms. Scoliosis may occur in adolescents, necessitating spinal fusion. While skeletal contractures can occur in all patients once they become wheelchair-dependent, they are a particular problem in ambulant ADEDMD and calpain-deficient muscular dystrophy (LGMD2A). Severe lower-limb contractures may compromise mobility.

Congenital muscular dystrophies

There are several recognized forms of congenital muscular dystrophy depending upon the protein/gene defect and/or the association of central abnormalities (see Table 10.2). They are usually caused by autosomal recessive genes and present at birth or in infancy with hypotonia and joint contractures, often involving the spine. The serum CK may be normal in some groups, and elevated in others. Intellect may be normal or impaired depending upon the presence of neuronal migration defects. White matter changes may be seen on magnetic resonance imaging (MRI) in cases with merosin deficiency, although there is normal intellect. Muscle biopsy shows dystrophic features and in some types specific protein abnormalities.

Clinical and diagnostic features

Reduced fetal movements during pregnancy suggest that signs are already present before birth, such infants are frequently born with arthrogryposis. Features in early infancy consist of muscle weakness and generalized hypotonia, ‘floppiness’, poor suck and respiratory difficulty (Kobayashi et al., 1996). In childhood, motor milestones are delayed, with severe and early contractures and often joint deformities. Weakness is greater in the pelvic girdle and upper leg muscles than in the shoulder girdle and upper arm muscles. On the whole, with the exception of Fukuyama congenital muscular dystrophy (FCMD), these conditions are relatively slowly progressive and functional ability can initially improve over time. Contractures at birth are common, and may restrict function to a greater degree than weakness if not controlled. It is particularly important to be vigilant for the insidious development of contractures and to treat them promptly.

Other features of the disease are hip dislocation, pes cavus and kyphoscoliosis. The motor development is slow, leading to late sitting, standing and walking, which is achieved in some but not all. Intelligence is normal in merosin deficient CMD and Ullrich CMD, but will be reduced in the muscle eye brain forms of CMD, where there are structural brain abnormalities, such as polymicrogyria and cerebellar cysts. Serum CK activity is usually very high in the early stages. In this group of patients vision should be assessed to exclude myopia and cataracts. In the Ullrich form of CMD intelligence and vision are normal, but there may be skin changes such as keloid scars or follicular hyperplasia.

Fascioscapulohumeral muscular dystrophy

This condition follows an autosomal dominant pattern of inheritance with a high degree of penetrance but variable expression. The clinical features are always present by 30 years of age. As many as 30% of cases present sporadically and are due to germ line mosaicism. The overall prevalence is estimated to be 1:20 000 (Kissell, 1999). In 95% of affected individuals, a short fragment on the telomeric portion of chromosome 4 (4q35) is identified (Wijmenga et al., 1991), which has been associated with a reduced number of 3.3-kb tandem repeat segments called D4Z4 in a non-protein-encoding region of the gene (Orrell et al., 1999). The size of the D4Z4 segment correlates inversely with clinical severity. The mechanism by which the reduced number of D4Z4 tandem repeats produce disease is unknown.

The age at onset, degree of severity and course of the disease are more variable than in many other neuromuscular diseases. Within a family it may range from someone who has minimal facial weakness with slow progression, to a condition which has a more marked progression of lower limb weakness that can cause severe disability early in life. Examination reveals facial weakness and a characteristic horizontal smile and inability to whistle. Shoulder-girdle weakness is often asymmetrical and more pronounced than lower limb weakness. Scapular winging with characteristic shoulder ‘terracing’ on abduction of the arms reflects weakness of serratus anterior, trapezius and rhomboids (Figure 10.3). The biceps and triceps muscles tend to be affected later.

The deltoid muscles are preserved in 50% of cases (Bunch & Siegel, 1993), but even if the deltoids are not involved the muscles lose their mechanical advantage due to lack of shoulder-girdle stability, causing limitation of active abduction and flexion. The patient may compensate surprisingly well, using trick movements to raise the hand above shoulder level, but can be more obviously compromised if the activity involves lifting objects of any weight. Foot drop may occur early in the disease due to peroneal and anterior tibial muscle weakness. Leg muscle weakness may eventually progress to loss of ambulation, which occurs in approximately 20% of cases. Joint contractures are rare and mild.

Cardiac involvement is uncommon and reported to occur in about 5% of cases; atrial arrhythmias are the most usual manifestation (Laforet et al., 1998). Sometimes the severe facial weakness may be mistaken for Moebius syndrome (Miura et al., 1998). The serum CK may be normal or three to five times the normal value. Confirmation of diagnosis can now be made with DNA analysis so that muscle biopsy is rarely necessary. Congenital onset is rare and can be associated with deafness, learning difficulties and severe muscle weakness.

General management

Studies of specific treatment for FSH are limited. Patients often develop a marked lumbar lordosis and low back pain due to pelvic girdle weakness, so that strengthening the pelvic musculature plus passive stretching exercises to minimize hip flexion contractures may be helpful. A recent study of mildy affected patients with FSH showed that low-intensity aerobic training over a 12-week period improved exercise performance (Olsen et al., 2005). Ankle–foot orthoses (AFOs) can be provided to control for foot drop, but may not be tolerated unless the ankle achieves plantigrade and quadriceps strength is at least antigravity (Eagle et al., 2001).

Thoracoscapular fusion can be effective in the long term for patients with scapular winging, provided the deltoid muscle remains functional (Rhee & Ha, 2006). More recently scapulothoracic fixation (scapulopexy) using wires to reposition the scapula over the ribs, without arthrodesis, has been shown to be successful (Gianinni et al., 2007). Both techniques result in improved range of movement and appearance of the shoulder and this is most beneficial for patients whose occupation specifically requires the ability to sustain flexion and abduction.

Myotonic dystrophy

Classical myotonic dystrophy (dystrophia myotonica; DM1) is a dominantly inherited multisystem disease that is relatively common, with a prevalence of 4 per 100 000 (Harper, 1989). DM1 is caused by an expansion of CTG repeats in the DMPK gene on chromosome 19q13 (Friedrich et al., 1987). The size of the expansion determines the severity of the phenotype and contributes to the phenomenon of anticipation, whereby the severity of the condition worsens in successive generations. This is especially obvious with the congenital form of the disease, where a severe and life-threatening phenotype occurs in the newborn infant, in contrast to the often presymptomatic mother.

The condition is classified according to the age of onset. The most severe congenital form presents at birth with contractures, respiratory and bulbar insufficiency and learning difficulty. The juvenile and classic forms of the disease present insidiously in the second and third decades with ptosis, frontal balding, myotonia (muscle stiffness) and muscle weakness (especially involving the facial, sternocleidomastoid and distal lower-limb muscles). Other features include: hypersomnolence, dysarthria, dysphagia, immune suppression, testicular atrophy, cataracts, digestive problems and diabetes. The most serious systemic complication is a cardiac conduction disorder, which can be a cause of sudden death.

At the mildest end of the spectrum cataracts or diabetes may be the only feature of the condition. Anaesthetic risks are significant in all cases, depolarizing muscle relaxants can lead to severe laryngospasm, and when given in combination with potent inhalational anaesthetics, a malignant hyperthermia reaction can occur (Moore & Moore, 1987). Myotonia is demonstrable by asking the patient to clench his or her fist and then let go quickly, the patient has to release their grip using the other hand. The EMG shows widespread myotonic discharges, which produce a classical dive-bomber sound caused by gradual fluctuations in frequency and amplitude (Fawcett & Barwick, 1994). The diagnosis is confirmed by DNA analysis.

Spinal muscular atrophies

The spinal muscular atrophies (SMAs) are a group of disorders in which there is degeneration of the anterior horn cells of the spinal cord, resulting in muscle weakness. They are the most common neuromuscular disease in childhood after DMD and affect both sexes. The mode of inheritance is mainly autosomal recessive but can vary, with dominant or X-linked traits (Emery, 1971). The genetic defect for the recessive form is a deletion in exon 7 and or exon 8 of the SMN1 gene on chromosome 5q (Ogino et al., 2004). Weakness is symmetrical, is greater proximally than distally, and the pelvic girdle is weaker than the shoulder girdle. Weakness is generally non-progressive, although as a result of increasing height and weight there may be some loss of functional activities over time. There is no facial weakness and intellectual development is often above normal. Classification of 5q SMA is most usefully based on clinical severity (Dubowitz, 1995):

Severe spinal muscular atrophy (type 1 or Werdnig–Hoffman disease)

Infants with severe type 1 SMA present within the first 6 months of life and usually by 3 months with hypotonia and feeding difficulties. The condition progresses rapidly and leads to severe muscle weakness with marked respiratory and bulbar involvement. As a result affected infants rarely survive beyond 2 years of age. Treatment is directed towards palliative care to control symptoms and support feeding. The infant is unable to move out of a lying position and the upper limbs adopt an internally rotated ‘jug-handle’ position and the lower limbs are flexed and abducted ‘frog position’. Limb contractures may develop related to these positions and, if untreated, activities such as dressing and lifting can become uncomfortable. Regular passive stretching techniques can become part of the daily routine at bath times and nappy changes. Moulding of the ribs can occur if the infant is always positioned on one particular side. This will further compromise respiratory capacity, and so alternation of sleeping positions is recommended.

The intercostal muscles are severely affected and breathing is almost entirely diaphragmatic, giving a characteristic bell-shaped chest. Cough is weak and bulbar weakness may give rise to sucking and swallowing difficulties. The child will be prone to recurrent respiratory infections. Parents should be taught secretion management techniques and they should be provided with suction. There is no place for spinal bracing or orthopaedic management in this group. Severe type 1 SMA is a devastating diagnosis and families need to be supported as much as possible. These very sick infants do not travel well and care should be delivered as close to home as possible.

Glycogen storage diseases

The glycogen storage diseases (GSDs) are characterized by abnormal glycogen metabolism.

Pompe disease

Pompe disease (acid maltase deficiency, GSD11) is a lysosomal storage disorder affecting muscle glycogen metabolism. The condition can present in infancy with a severe phenotype, resulting in progressive muscle weakness and cardiomyopathy. Death usually occurs by 2 years of age from cardiac and respiratory failure. Early diagnosis is essential for a good outcome with enzyme replacement with myozyme (Nicolino et al., 2009). Less severe forms of GSD11 present during childhood (juvenile-onset) and adulthood. The condition is milder with a slower progression, causing limb girdle weakness, which closely resembles LGMD or mild SMA. Respiratory failure due to both diaphragmatic involvement and cardiomyopathy occurs and can be disproportionate to the skeletal weakness. Regular cardiorespiratory monitoring is therefore recommended. Enzyme replacement therapy is available for all forms of Pompe disease, although the evidence for benefit is currently based upon the treatment of the severe infantile form.

Inflammatory myopathies

Inflammatory myopathies can be divided into three distinct groups:

DM and PM have an autoimmune aetiology and respond well to immuno-suppressive agents; IBM occurs in older people, it is usually sporadic and does not always respond to immunesuppression. There are two rare subtypes of inherited IBM in younger patients, caused by homozgous mutations in the GNE gene, while in older patients a rare genetic form with mutations in VCP is associated with Pagets disease and dementia (Phadke et al., 2009; Vesa et al., 2009).

DM is an inflammatory muscle condition associated with a characteristic facial rash occurring around the eyes (heliotrope rash). The condition affects children between the ages of 5 and 15 years. A second peak in incidence occurs in middle and old age, and is frequently associated with an underlying malignancy (Callen, 1988). The disease is characterized by muscle pain and proximal weakness, joint contractures can develop rapidly. The serum CK and erythrocyte sedimentation rate may be elevated, and a muscle biopsy confirms the inflammatory process. Treatment includes immune suppression and physiotherapy to minimize contractures.

PM presents with subacute proximal weakness, without myalgia and rash. The condition may occur as part of a more generalized autoimmune connective tissue disease and can also be precipitated by some drugs, including penicillamine and zidovudine (AZT). Muscle biopsy confirms an inflammatory myopathy and patients respond to corticosteroids and immune suppression.

IBM occurs more commonly in males most often over the age of 50. IBM should be suspected when a patient with an inflammatory myopathy fails to respond to corticosteroids. Unlike DM and PM, there may be facial weakness and there is frequently distal weakness, especially of the finger flexors and foot extensors, in addition to proximal weakness. About 20% of cases will be associated with an underlying autoimmune connective tissue disorder.

Physical management of neuromuscular disorders

This section highlights the areas of management which are specific to muscle disorders, both in adulthood and childhood. Details of treatment concepts and techniques are found in Chapters 11 & 12, respectively. A problem-solving approach is preferable and treatment planning should involve the multidisciplinary team (MDT), the patient, parents and carers.

Assessment

Thorough, standardized and regular assessment of neuromuscular patients is essential because of the progressive nature of many conditions and the superimposed effect of growth on children. Assessment will guide clinical management and evaluate therapeutic outcome for research purposes. The key aspects of assessment are measurement of muscle strength and performance and lung function; the principles of assessment are discussed in Chapter 1 (also see Ryerson, 2009; Stokes, 2009).

Measurement of muscle strength

Strength assessment provides information for the planning and monitoring of intervention as well as diagnostic information.

Manual muscle testing

Manual muscle testing is the most widely used means of assessing muscle strength and has been recommended as an outcome measure for therapeutic trials in neuromuscular disease (Brooke et al., 1981). The Medical Research Council scale of grading muscle strength is the most widely known grading system and is based on an ordinal scale of 0 to 5. No special equipment is required and manual muscle testing is a rapid method of determining the distribution and severity of weakness over a large number of muscle groups. However, the major criticism of this method is its subjectivity. There are no standardized joint positions at which testing should be performed and the point at which counterforce is administered is also self-selected. The proportion of maximum strength required to overcome gravity is markedly different between muscle groups (Wiles et al., 1990), and a loss of strength in excess of 50% may develop before weakness can be detected by manual muscle testing (Fisher et al., 1990).

Dynamometry

Force can be measured directly with dynamometers; these quantitative measurements of muscle force are superior to manual muscle testing and provide the most direct method of assessing a particular muscle group. A hand-held dynamometer can measure maximal isometric strength and the results are highly reproducible provided standardized techniques are used and the same observer performs the measurement on each occasion (Bohannon, 1986; Lennon & Ashburn, 1993). Serial measurements of a single patient will be the most useful means of evaluating the distribution and rate of change of muscle weakness, whilst the degree of weakness can be established by comparison with published normal values of muscle strength (Beenacker et al., 2001). Hand-held dynamometers are useful only when muscles are weak, since their use is restricted by the strength of the operator to oppose the patient’s efforts. Strain gauges attached to rigs, and also commercially available isometric and isokinetic machines, are available.

Motor ability tests

Classically the most commonly used measures of motor ability have been those developed for DMD by Vignos et al. (1963), Brooke et al. (1981) and the Hammersmith Motor Ability Scale (HMAS) (Scott et al., 1982). The Vignos scale was originally designed as a functional classification and its sensitivity as an objective measure of function is doubtful. The HMAS has been widely used in clinical practice, although there is little published information about its reliability and validity. This scale has recently been modified, is now known as the ‘North Star Ambulatory Assessment’ and been shown to have excellent inter-observer reliability (Mazzone et al., 2009). Its 17 motor activities are biased towards activities involving the lower limbs, making it suitable for assessment of ambulant patients (Table 10.3). The patient sequentially performs a succession of movements that are scored on a 3-point scale which can be completed in 15 minutes. A functional test, the EK scale, for non-ambulant patients with DMD has been shown to be reliable by Steffensen et al. (2002).

Table 10.3 North Star Amulatory Assessment

Test Item Score
1. Stand  
2. Walk (10 m)  
3. Sit to stand from chair  
4. Stand on one leg – R  
5. Stand on one leg – L  
6. Climb step – R  
7. Climb step – L  
8. Descend step – R  
9. Descend step – L  
10. Gets to sitting  
11. Rise from floor  
12. Lifts head  
13. Stand on heels  
14. Jump  
15. Hop – R  
16. Hop – L  
17. Run  
TOTAL SCORE  

Scores: 2 – ‘Normal’: achieves goal without assistance; 1 – Modified method but achieves goal independent of physical assistance from another; 0 – Unable to achieve independently. R, right leg; L, left leg

(Reprinted from Mazzone ES, Messina S, Vasco G et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscular Disorders, 2009; 19:458-461, with permission from Elsevier.)

Timed tests

Timed performance tests are commonly used as supplementary measures of physical performance as a means of reflecting progressive weakness (Brooke et al., 1981). A timed walk over a fixed distance or time, such as the 10 m test or the 6 minute walk test, can reliably detect changes over time (Mazzone et al., 2009). The 10 m walk test can predict loss of ambulation (McDonald et al., 1995). Timing the Gowers’ manoeuvre is a useful measure of changing function and supine lying is a more reproducible starting position than is sitting.

Treatment principles

The benefits of an active approach to the physical management of neuromuscular disease are increasingly recognized. These include not only minimizing complications in order to maximize abilities, but also maintaining the patient in the best possible physical condition so that he or she could benefit from new treatments; developments in translational research make this a realistic possibility.

The main principles of treatment are:

Treatment concepts (see Ch. 11) and details of techniques (see Ch. 12) are not discussed here, but the principles relevant to patients with muscle disorders are outlined.

Maintenance of muscle strength

There are very few controlled studies on the effect of exercise in neuromuscular disease and many are not disease specific. The results of mild to moderate resistance exercise programmes in muscular dystrophies have shown limited increases in strength, with no negative effect on muscle function (Ansved, 2003). Greatest effects occur in patients with mild to moderate weakness and in the more slowly progressive conditions, whilst patients with severely weak muscles do not generally benefit from strengthening programmes. It appears in normal subjects that a prerequisite for successful strength training is a high content of type II fibres (Jones et al., 1989). The relative deficiency of type II fibres in DMD (Dubowitz, 1985) may contribute to the poor force-generating capacity of dystrophic muscle and could also be a limiting factor in the eventual benefit of a strengthening programme.

Consistent reductions in maximal or peak oxygen uptake, pulmonary ventilation, work capacity and endurance have been reported in both rapidly and slowly progressive neuromuscular disorders (Kilmer, 2002). Short-term studies in disease-specific patients (Olsen et al., 2005; Sveen et al., 2007; Sveen et al., 2008) indicate low to moderate intensity aerobic exercise is well tolerated with functional improvements in aerobic capacity.

Eccentric muscle training is increasingly being used in the training of athletes to facilitate the development of muscle power, i.e. the rate of force generation. However, eccentric exercise can cause appreciable morphological damage to muscle fibres (Newham et al., 1986) and damage of this nature is commonly seen in the muscles of patients with myopathic diseases. Whilst normal muscle recovers from this damage, eccentric exercise would seem best avoided in muscle disease in favour of more traditional concentric protocols.

Edwards et al. (1987) documented important differences in the rate of progression of various muscle groups and highlighted a particularly rapid loss of force in the hip and knee extensors. Insufficiency of these muscle groups has been shown to be the key deficit in functional decline and gait deterioration in DMD (Sutherland et al., 1981). Whilst maximizing muscle strength to achieve optimal or improved functional ability is a primary objective of treatment, the effect of specific muscle strengthening programmes on function in neuromuscular disorders awaits objective evaluation. To devise a strengthening programme, the required functional gain should be considered and appropriate muscle groups targetted.

It is well accepted that in normal individuals physical exercise increases muscle strength, whilst inactivity causes de-conditioning, and there is also widespread observation amongst clinicians that severe restriction of activity causes rapid weakening of muscle in dystrophic conditions and should be avoided. It is therefore important that the duration of enforced immobilization during any acute illness, and after surgery, should be kept to a minimum so that the patient’s return to mobility is not compromised by muscle atrophy. Exercise and strength training in patients with neuromuscular disorders is discussed in Chapter 18.

Weakness occurs when a muscle is held in a shortened position due to joint deformity, and also when it is contracting over a reduced range (Gossman et al., 1982). The establishment of compensatory postures, long before the development of fixed contracture, means that the muscle is biomechanically disadvantaged earlier than is obvious, since it is continually contracting over a shortened range. This could be a major factor in further progression of the disease as optimal function of the muscle is prevented. Joint positioning during strengthening may therefore be important but research in these patients is still required.

Electrical stimulation of normal muscle can improve strength and fatiguability but evidence that the technique is safe, as well as beneficial, in muscle disorders has yet to be produced (see Chapter 12).

Retarding contracture progression

The management of contractures is one of the major contributions of physiotherapy in neuromuscular disease. The aim is not only to retard the progression of contracture, but also and more importantly to promote or prolong independent ambulation and functional ability. Impairment of mobility caused by contractures compromises the strength of the muscles working across the involved joint or joints. The force-generating ability of a muscle is influenced by the length at which it contracts (Jones & Round, 1990) and thus the strength of a muscle held in a shortened position is reduced. In the presence of profound weakness, the maintenance of full joint range of motion is essential for optimal muscle function.

A sustained programme of night splinting and passive stretching in the early stages of DMD can retard the development of lower limb contractures. Two studies have specifically evaluated the effect of passive stretching and the use of orthoses on the development of contractures. Both concluded that the combination of passive stretching and night splints are more effective than passive stretching alone at delaying contractures and prolonging independent ambulation (Hyde et al., 2000; Scott et al., 1981).

Whilst independently ambulant, the provision of AFOs for control of Achilles tendon contracture should be confined to night use only. Gait analysis has shown that an equinus position of the foot is used as a compensatory manouevre to increase knee stability during walking. Khodadadeh et al. (1986) observed that boys with DMD necessarily adopt a dynamic equinus during gait in order to maintain a knee-extending moment in the presence of gross quadriceps weakness. AFOs intended to correct the foot position by reducing the equinus during walking will have biomechanical effects which will de-stabilize the knee. If there is significant quadriceps weakness the knee will buckle. Thus AFOs used in this way reduce the available compensatory manoeuvres and result in premature loss of ambulation.

Promoting or prolonging ambulation

Following the cessation of independent walking, the duration of useful ambulation in children can be prolonged with an immediate programme of percutaneous Achilles tenotomy and rehabilitation in lightweight KAFOs and intensive physiotherapy (Figure 10.2). The gains in additional walking time have varied in different centres but on average an extra 2 years of walking can be achieved and sometimes up to 4 years (Bakker et al., 2000). This approach is now generally accepted as a means of maintaining mobility after independent walking ceases and has been shown to impede the development of both lower limb contractures (Vignos et al., 1996) and scoliosis (Rodillo et al., 1988).

The accurate timing of intervention and prompt provision of orthoses are crucial to the success of prolonging ambulation (Thompson et al., 2007). The optimal time for the provision of the orthoses is when the child has lost useful walking but is still able to stand or walk a few steps. There is no advantage in providing orthoses earlier than this. Two of the important factors used to predict successful outcome are the absence of severe hip and knee contractures, and the percentage of residual muscle strength (Hyde et al., 1982). Swivel walkers may be appropriate to allow movement over short distances at home or school. Once the child has been wheelchair-bound for even a short time, fixed lower limb deformities and muscle weakness rapidly progress, and therefore any delay in undertaking this programme may compromise a successful outcome.

Management of scoliosis

Scoliosis is a serious complication of DMD and intermediate SMA. Whilst scoliosis is also associated with other neuromuscular disorders, it is rapidly progressive in these two conditions unless it is treated.

In DMD, a progressive scoliosis almost always develops once the child loses the ability to walk. The period of most rapid deterioration corresponds most closely with the adolescent growth spurt between the ages of 12 and 15 years (McDonald et al., 1995). Progressive scoliosis is also a threat in the adolescent years of patients with type 3 SMA, but due to the profound weakness that is present from early infancy in patients with type 2 SMA it may become a problem at a much earlier age.

The curve often develops in a paralytic long C pattern in the thoraco-lumbar areas and is associated with increasing pelvic obliquity. It further compromises respiratory capacity, which is already restricted by involvement of the respiratory muscles (Kurz et al., 1983). An increasing scoliosis also leads to difficulty in sitting and maintaining head control, and can cause discomfort and pressure areas. Patients will often need to use their elbows for support in maintaining an upright position, so preventing them from using the arms for other functions such as feeding. Untreated, the scoliosis may cause patients to become bedridden.

One of the major benefits of treatment aimed at maintaining an upright posture is that it will help to delay the progression of scoliosis. Once the patient is dependent on a wheelchair, the main means of managing scoliosis are conservative, using a spinal orthosis, or by spinal fusion. The spine should be monitored carefully where scoliosis is a likely complication of the disease, in conjunction with the respiratory capacity using simple spirometry. Once a curve is clinically apparent, any progression is most accurately measured from radiographs using Cobb’s angle. Prompt provision of a spinal orthosis is advisable, to be worn during the day whilst the patient is upright and should be corrective rather than supportive. It is recognized that spinal bracing is not the definitive treatment in curves that are known to be rapidly progressive, but it is important in slowing the rate of progression of the curvature (Seeger et al., 1990) and can be used effectively for skeletally immature patients in whom spinal fusion is not yet indicated.

Posterior spinal fusion is used widely in the management of progressive scoliosis in neuromuscular disease and provides rigid fixation without the need for post-operative immobilization or orthoses. It is effective in achieving maximum curve correction and minimizing respiratory complications. Early surgery is the treatment of choice while respiratory and cardiac function is adequate to undergo the procedure safely. In DMD vital capacity increases with age and growth in the early years, reaches a plateau, and then declines in the early teens. There is therefore a window of opportunity when surgery can be performed safely and this is usually when the curve is 20–40° (Cobb angle) and forced vital capacity is above 30% (Manzur et al., 2008b). Spinal fusion is associated with slowing of the rate of respiratory decline postoperatively, as well as enhanced comfort and seating (Velasco et al., 2007). It has recently been reported that patients with low vital capacity can safely undergo spinal surgery provided it is undertaken in a specialist centre (Gill et al., 2006; Marsh et al., 2003).

In the immediate postoperative period, respiratory therapy to aid removal of secretions will be necessary in patients with a poor cough (see Ch. 15). It is possible for a lumbar lordosis and dorsal kyphosis to be moulded into the rods (Galasko et al., 1992), which helps prevent loss of head control in sitting when weakness of the neck and trunk musculature is likely to be advanced. However, seating requirements will need to be reassessed postoperatively, for example, due to significant upper limb weakness the child is likely to utilize upper trunk flexion to help get his or her mouth down to his or her hands for feeding purposes. Following surgery the height of wheelchair arm supports or table height will need to be adjusted to compensate for a fused spine.

Management of respiratory complications

Chest infections are a serious complication to vulnerable patients with respiratory muscle weakness and a poor cough. Longstanding weakness may lead to more serious secondary problems including widespread microatelectasis with reduced lung compliance, a ventilation perfusion imbalance, and nocturnal hypoxaemia (Smith et al., 1991).

Chest infections should be treated promptly with physiotherapy, postural drainage, antibiotics and, when appropriate, assisted ventilation (see Ch. 15). Spinal orthoses that control scoliosis may reduce respiratory capacity and should be temporarily removed if causing distress or interfering with treatment. The aim of treatment is to help clear the lungs of secretions effectively in the shortest possible time without causing fatigue. Thoracic expansion exercises will allow increased airflow through small airways and the loosening of secretions, while forced expiration techniques, the use of intermittent positive pressure breathing (IPPB) and assisted coughing will aid removal of secretions (Webber, 1988). Diaphragmatic weakness may limit the use of supine or tipped positions for postural drainage. Parents of children prone to recurrent chest infections can become competent at administering chest physiotherapy but will require support that is readily accessible if children become distressed.

Inspiratory muscle training has been reported by some to improve respiratory force and endurance (Martin et al., 1986; Wanke et al., 1994), an effect which may be dose dependent (Topin et al., 2002), whereas others report no significant effects (Rodillo et al., 1989; Stern et al., 1989). Overall training is best started in the early stages of DMD where there is only moderate impairment of lung function. This approach does not appear to be used regularly in clinical practice and has probably been superceded by the successful use of nocturnal ventilation at a later stage.

Respiratory failure may be precipitated by chest infection or it may occur as a result of increasing nocturnal hypoventilation and hypoxia. The onset is often insidious but symptoms include morning drowsiness, headache or confusion and nighttime restlessness, and can be confirmed by sleep study. Life expectancy is less than 1 year once diurnal hypercapnia develops. Symptoms, quality of life and survival can be improved by non-invasive nasal ventilation (Eagle et al., 2002; Simonds, 2000).

‘Social’ and psychological issues in neuromuscular disorders

A complexity of factors influences management at different stages of the patient’s life. For lifelong disorders, these influences pose similar problems as in other disabling conditions, such as cerebral palsy or spina bifida (see Shepherd, 1995). The need for more training and support for professionals managing these patients was highlighted in a survey by Heap et al. (1996).

Transition from childhood to adulthood

There is a lack of provision of services for the young disabled adult. On leaving school, the support system often ceases and, apart from occasional visits to the hospital consultant, physiotherapy and other services are not always offered. Patients whose disorder begins in adulthood may never be offered any services or treatment, or even referred to a specialist, despite having a significant disability.

There is a need for specialist centres to provide advice and treatment from experienced therapists and offer an environment for social interaction and training for vocational and leisure activities. This would enable children to continue with their physical management programmes as adults, taking responsibility for their own treatment but receiving help for monitoring and modification of treatment. Those with disorders of adult onset could be educated in physical management strategies by therapists and other patients, and learn how to maximize their abilities and remain functional for as long as possible. Other areas, such as weight control and sexual counselling, could also be dealt with or referral made where appropriate.

Patients with neuromuscular disorders, particularly adults, often feel isolated in the community and some do not lead as full a life as they have the potential for because of a lack of support and education about their condition. Some give up employment or even going out of the house. Specialist centres could provide an important function and fill a major gap in care and support.

In the terminal stage of illness, support from the care team, particularly the general practitioner, is essential and bereavement counselling may be required. The Muscular Dystrophy Campaign Family Care Officers (see ‘Association and Support Groups’) play a very important role at all stages, particularly during the final illness, in guiding and supporting families.

References

Ansved T. Muscular dystrophies: influence of physical conditioning on the disease evolution. Curr. Opin. Clin. Nutr. Metab. Care. 2003;6:435-439.

Armand S., Mercier M., Watelain E., Patte K., Pelissier J., Rivier F. Gait pattern in Duchenne muscular dystrophy. Gait Posture. 2009;29(1):36-41. Epub 2008 Jul 25

Bakker J.P.J., De Groot I.J.M., Beckerman H., de Jong B.A., Lankhorst G.J. The effects of knee-ankle-foot-orthoses in the treatment of Duchenne muscular dystrophy: review of the literature. Clin. Rehabil.. 2000;14:343-359.

Bialer M.G., McDaniel N.L., Kelly T.E. Progression of cardiac disease in Emery–Dreifuss muscular dystrophy. Clin. Cardiol.. 1991;14(5):411-416.

Beenakker E.A., van der Hoeven J.H., Fock J.M., et al. Reference values of maximum isometric force obtained in 270 children aged 4-16 years by hand-held dynamometry. Neuromuscul. Disord.. 2001;11(5):441-446.

Beynon R., Quinlivan R.C.M., Sewry C.A. Selected disorders of carbohydrate metabolism. In: Karpati G., editor. Structural and Molecular Basis of Skeletal Muscle Diseases. Basel: ISN Neuropath Press; 2002:182-188.

Bertorini T.E., et al. Diagnostic Criteria for Duchenne’s Muscular Dystrophy. In: Clinical Evaluation and Diagnostic tests for Neuromuscular Disorders. Butterworth-Heinemann Press; 2002:784.

Biggar W.D., Harris V.A., Eliasoph L., et al. Long term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul. Disord.. 2006;16:249-255.

Bohannon R.W. Test–retest reliability of hand-held dynamometry during a single session of strength assessment. Phys. Ther.. 1986;66:206-209.

Bonne G., Di Barletta M.R., Varnous S., et al. Mutations in the gene encoding lamin A/C cause Autosomal Dominant Emery-Dreifuss muscular dystrophy. Nat. Genet.. 1999;21:285-288.

Bradley W.G., Jones M.Z., Fawcett P.R.W. Becker Type muscular dystrophy. Muscle Nerve. 1978;1:111-132.

Brooke M.H., Griggs M.D., Mendell J.R., et al. Clinical trial in Duchenne dystrophy. 1. The design of the protocol. Muscle Nerve. 1981;4:186-197.

Bunch W.H., Siegel I.M. Scapulothoracic arthrodesis in Fascioscapulohumeral Muscular Dystrophy. J. Bone Joint Surg. Am.. 1993;75A:372-376.

Callen J.P. Malignancy in polymyositis / dermatomyositis. Clinical Dermatology. 1988;2:55-63.

Carroll N., Bain R.J.I., Smith P.E.M., et al. Domiciliary investigation of sleep-related hypoxaemia in Duchenne muscular dystrophy. Eur. Respir. J.. 1991;4:434-440.

Carter G.T., Abresch R.T., Fowler W.M., et al. Profiles of neuromuscular disease: Spinal muscular atrophy. Am. J. Phys. Med. Rehabil.. 1995;74:150-159.

D’Angelo M.G., Berti M., Piccinini L., et al. A comparison of gait in spinal muscular atrophy, type II and Duchenne muscular dystrophy. Gait Posture. 2005;21(4):369-378.

Duboc D., Meune C., Pierre B., Wahbi K., Eymard B., Totain A., et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years follow-up. Am. Heart J.. 2007;154:596-602.

Dubowitz V. Muscle biopsy: A practical approach, second ed. London: Ballière Tindall, 1985.

Dubowitz V. Muscle disorders in childhood, second ed. London: WB Saunders, 1995.

Eagle M., Baudouin S.V., Chandler C., et al. Survival in Duchenne muscular dystrophy; improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul. Disord.. 2002;12:926-930.

Eagle M., Bourke J., Bullock R., et al. Managing Duchenne muscular dystrophy – the additive effect of spinal surgery and home ventilation in improving survival. Neuromuscul. Disord.. 2007;17:470-475.

Eagle M., Peacock C.K., Bushby K., Major R., Clements P. Fascioscapuohumeral muscular dystrophy: gait analysis and effectiveness of ankle foot orthoses (AFOs) (abstract). Neuromuscul. Disord.. 2001;11(6–7):631.

Edwards R.H.T., Chapman S.J., Newham D.J., et al. Practical analysis of variability of muscle function measurements in Duchenne Muscular Dystrophy. Muscle Nerve. 1987;10:6-14.

Emery A.E.H. The nosology of the spinal muscular atrophies. J. Med. Genet.. 1971;8:481-495.

Emery A.E.H. Population frequencies of inherited neuromuscular diseases– a world survey. Neuromuscul. Disord.. 1991;1:19-29.

Emery A.E., Muntoni F. Duchenne Muscular Dystrophy. Oxford: Oxford University Press, 2003.

Fawcett P.R.W., Barwick D.D. The clinical neurophysiology of neuromuscular disease. In: Walton J.N., Karpati G., Hilton-Jones D., editors. Disorders of voluntary muscle. sixth ed. Edinburgh: Churchill Livingstone; 1994:1033-1104.

Fisher N.M., Pendergast D.R., Calkins E.C. Maximal isometric torque of knee extension as a function of muscle length in subjects of advancing age. Arch. Phys. Med. Rehabil.. 1990;71:729-734.

Friedrich U., Brunner H., Smeets D., et al. Three points linkage analysis employing C3 and 19cen markers assign the myotonic dystrophy gene to 19q. Hum. Genet.. 1987;75:291-293.

Galasko C.S.B., Delaney C., Morris P. Spinal stabilisation in Duchenne Muscular Dystrophy. J. Bone Joint Surg.. 1992;74B:210-214.

Gianinni S., Faldini C., Pagkrati S., Grandi G., Digennaro V., Luciani D., et al. Fixation of winged scapula in facioscapulohumeral muscular dystrophy. Clin. Med. Res.. 2007;5(3):155-162.

Gill I., Eagle M., Jwalant S., et al. Correction of neuromuscular scoliosis in patients with pre-existing respiratory failure. Spine. 2006;21:2478-2483.

Gospe S.M., Lazaro R.P., Lava N.S., et al. Familial X linked myalgia and cramps: a non-progressive myopathy associated with a deletion in the dystrophin gene. Neurology. 1989;39:1277-1280.

Gossman M.R., Sahrmann S.A., Rose S.J. Review of length associated changes in muscle. Phys. Ther.. 1982;62:1799-1808.

Griggs R.C., Donohoe K.M., Utell M.J., et al. Evaluation of pulmonary function in neuromuscular disease. Arch. Neurol.. 1981;38:9-12.

Harper P.S. Myotonic dystrophy, second ed. Philadelphia: WB Saunders, 1989.

Heap R.M., Mander M., Bond J., et al. Management of Duchenne muscular dystrophy in the community: views of physiotherapists, GP’s and school teachers. Physiotherapy. 1996;82:258-263.

Hough A. Physiotherapy in respiratory care. London: Chapman & Hall, 1991.

Hunsaker R.H., Fulkerson P.K., Barry F.J., et al. Cardiac function in Duchenne’s muscular dystrophy. Results of 10–year follow up study and noninvasive tests. Am. J. Med.. 1982;73:235-238.

Hyde S.A., Fløytrup I., Glent S., et al. A randomised comparative study of two methods of controlling tendo achilles contracture in Duchenne muscular dystrophy. Neuromuscul. Disord.. 2000;10:257-263.

Hyde S.A., Scott O.M., Goddard C.M., et al. Prolongation of ambulation in Duchenne muscular dystrophy. Physiotherapy. 1982;68:105-108.

Illarioshkin S.N., Ivanova-Smolenskala I.A., Tanaka H. Refined genetic location of the chromosome 2p linked progressive muscular dystrophy gene. Genomics. 1997;42:345-348.

Jeppesen J., Green A., Steffensen B.F., Rahbek J. The Duchenne muscular dystrophy population in Denmark, 1977–2001: prevalence, incidence and survival in relation to the introduction of ventilator use. Neuromuscul. Disord.. 2003;13(10):804-812.

Jones D.A., Round J.M. Skeletal muscle in health and disease. Manchester: Manchester University Press, 1990.

Jones D.A., Rutherford O.M., Parker D.F. Physiological changes in skeletal muscle as a result of strength training. Q. J. Exp. Physiol.. 1989;74:233-256.

Karpati G., Hilton-Jones D., Griggs R.C. Disorders of Voluntary Muscle, seventh ed. Cambridge University Press, 2001.

Khodadadeh S., McClelland M.R., Patrick J.H., et al. Knee moments in Duchenne muscular dystrophy. Lancet. 1986;6(September):544-555.

Kilmer D.D. Response to aerobic exercise training in humans with neuromuscular disease. Am. J. Phys. Med. Rehabil.. 2002;81(Suppl. 11):S187-S195.

Kissell J.T. Fascioscapulohumeral dystrophy. Semin. Neurol.. 1999;19:35-43.

Kobayashi O., Hayashi Y., Arahata K., et al. Congenital muscular dystrophy. Neurology. 1996;46:815-818.

Kurz L.T., Mubarek S.J., Schultz P. Correlation of scoliosis and pulmonary function in Duchenne muscular dystrophy. J. Pediatr. Orthop.. 1983;3:347-353.

Laforet P., De Toma C., Eymard B., et al. Cardiac involvement in genetically confirmed Fascioscapulohumeral muscular dystrophy. Neurology. 1998;51:1454-1456.

Lennon S.M., Ashburn A. Use of myometry in the assessment of neuropathic weakness: testing for reliability in clinical practice. Clin. Rehabil.. 1993;7:125-133.

Main M., Mercuri E., Haliloglu G., et al. Serial casting of the ankles in Duchenne muscular dystrophy: can it be an alternative to surgery? Neuromuscul. Disord.. 2007;17:227-230.

Manzur A.Y., Kuntzer T., Pike M., Swan A. Glucocorticosteroids for Duchenne muscular dystrophy. The Cochrane Library. (1):2008. CD 003725

Manzur A.Y., Kinali M., Muntoni F. Update on the management of Duchenne muscular dystrophy. Arch. Dis. Child.. 2008;93:986-990.

Marsh A., Edge G., Lehovsky J. Spinal fusion in patients with Duchenne’s muscular dystrophy and a low forced vital capacity. Eur. Spine J.. 2003;12(5):507-512.

Martin A.J., Stern L., Yeates J., et al. Respiratory muscle training in Duchenne Muscular Dystrophy. Dev. Med. Child. Neurol.. 1986;28:314-318.

Mastaglia F.L., Laing N.G. Investigation of muscle disease. J. Neurol. Neurosurg. Psychiatry. 1996;60:256-274.

Mazzone E.S., Messina S., Vasco G., et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul. Disord.. 2009;19:458-461.

McDonald C.M., Abresch R.T., Carter G.T., et al. Profiles of neuromuscular disease. Duchenne muscular dystrophy. Am. J. Phys. Med. Rehabil.. 1995;74:70-92.

Mehdian H., Shimizu N., Draycott V., et al. Spinal stabilisation for scoliosis in Duchenne muscular dystrophy. Experience with various sublaminar instrumentation systems. Neuro-Orthopedics. 1989;7:74-82.

Miura K., Kumagai T., Matsumoto A., Iriyama E., Watanabe K., Goto K., et al. Two cases of chromosome 4q35-linked early onset fascioscapulohumeral muscular dystrophy with mental retardation and epilepsy. Neuropaediatrics. 1998;29:239-241.

Moore J.K., Moore A.P. Postoperative complications of dystrophia myotonica. Anaesthesia. 1987;42:529-533.

Muntoni F., Torelli S., Ferlini A. Dystrophin and mutations: one gene,several proteins, multiple phenotypes. Lancet Neurol.. 2003;2:731-740.

Newham D.J., Jones D.A., Edwards R.H.T. Plasma creatinine kinase changes after eccentric and concentric contractions. Muscle Nerve. 1986;9:59-63.

Nicolino M., Byrne B., Wraithe J.E., Leslie N., Mendel H., Freyer D.R., et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet. Med.. 2009;11:210-219.

Nigro G., Comi L.I., Politano L., et al. The incidence and evaluation of cardiomyopathy in Duchenne muscular dystrophy. Int. J. Cardiol.. 1990;26:271-277.

Ogino S., Wilson R.B., Gold B. New insights on the evolution of the SMN1 and SMN2 region simulation and meta-analysis for allele and haplotype frequency calculations. Eur. J. Hum. Genet.. 2004;12:1015-1023.

Olsen D.B., Orngreen M.C., Vissing J. Aerobic training improves exercise performance in fascioscapulohumeral dystrophy. Neurology. 2005;64:1064-1066.

Orrell R.W., Forrester J.D., Tawil R., et al. Definitive molecular diagnosis of fascioscapulohumeral muscular dystrophy. Neurology. 1999;52:1822-1826.

Pandya S., Florence J.M., King W.M., et al. Reliability of goniometric measurements in patients with Duchenne muscular dystrophy. Phys. Ther.. 1985;65:1339-1342.

Phadke A.P., Jay C., Chen S.J., Haddock C., Wang Z., Yu Y., et al. Safety and in vivo Expression of a GNE-Transgene: A Novel Treatment Approach for Hereditary Inclusion Body Myopathy-2. Gene Regulation and Systems Biology. 2009;3(May):89-101.

Phillips M.F., Quinlivan R.C.M., Edwards R.H.T., et al. Changes in spirometry over time as a prognostic marker in patients with Duchenne Muscular Dystrophy. American Journal of Critical Care Medicine. 2001;164:2191-2194.

Pope P.M. Postural management and special seating. In: Edwards S., editor. Neurological physiotherapy: a problem solving approach. second ed. London: Churchill Livingstone; 2002:189-217.

Quinlivan R.M., Dubowitz V. Cardiac transplantation in Becker muscular dystrophy. Neuromuscul. Disord.. 1992;2(3):165-167.

Rhee Y.G., Ha J.H. Long-term results of scapulothoracic arthrodesis of fascioscapulohumeral muscular dystrophy. J. Shoulder Elbow Surg.. 2006;15(4):445-450.

Rodillo E.B., Fernandez-Bermejo E., Heckmatt J.Z., et al. Prevention of rapidly progressive scoliosis in duchenne muscular dystrophy by prolonging walking with orthoses. J. Child. Neurol.. 1988;3:269-274.

Rodillo E., Noble-Jamieson C.M., Aber V., et al. Respiratory muscle training in Duchenne muscular dystrophy. Arch. Dis. Child.. 1989;64:736-738.

Ryerson S. Neurological assessment: the basis of clinical decision making. In: Lennon S., Stokes M., editors. Pocketbook of Neurological Physiotherapy. Churchill Livingstone; 2009:113-126.

Scott O.M., Hyde S.A., Goddard C., et al. Prevention of deformity in Duchenne muscular dystrophy. Physiotherapy. 1981;67:177-180.

Scott O.M., Hyde S.A., Goddard C., et al. Quantitation of muscle function in children: a prospective study in Duchenne Muscular Dystrophy. Muscle Nerve. 1982;5:291-301.

Seeger B.R., Sutherland A., Clark M.S. Management of scoliosis in Duchenne muscular dystrophy. Arch. Phys. Med. Rehabil.. 1990;65:83-86.

Shepherd R.B. Physiotherapy in Paediatrics, third ed. Oxford: Butterworth Heinnemann, 1995.

Simonds A.K. Nasal ventilation in progressive neuromuscular disease: experience in adults and adolescents. Monaldi Archives of Chest Disease. 2000;55(3):237-241.

Smith P.E.M., Edwards R.H.T., Calverley P.M.A. Mechanisms of sleep-disordered breathing in chronic neuromuscular disease: implications for management. Q. J. Med.. 1991;296:961-973.

Steare S.E., Benatar A., Dubowitz V. Subclinical cardiomyopathy in Becker muscular dystrophy. Br. Heart J.. 1992;68:304-308.

Steffensen B.F., Hyde S.A., Attermann J., et al. Reliability of the EK scale; a functional test for non-ambulatory individuals with Duchenne muscular dystrophy. Adv. Physiother.. 2002;4:47.

Stern L.M., Martin A.J., Jones N., et al. Training inspiratory resistance in Duchenne dystrophy using adapted computer games. Dev. Med. Child. Neurol.. 1989;31:494-500.

Stokes E.K. Outcome measurement. In: Lennon S., Stokes M., editors. Pocketbook of Neurological Physiotherapy. Churchill Livingstone; 2009:192-201.

Sutherland D.H., Olshen R., Cooper L., et al. The pathomechanics of gait in Duchenne muscular dystrophy. Dev. Med. Child. Neurol.. 1981;23:3-22.

Sveen M.L., Jeppesen T.D., Hauersley S., Krag T.O., Vissing J. Edurance training. An effective and safe treatment for patients with LGMD21. Neurology. 2007;68:59-61.

Sveen M.L., Jeppesen T.D., Hauerslev, et al. Endurance training improves fitness and strength in patients with Becker muscular dystrophy. Brain. 2008;131:2824-2831.

Thompson N., Porter S., Morris C. Muscular Dystrophies, Spinal Muscular Atrophies and Peripheral Neuropathies. In: Morris C., Dias L., editors. Paediatric Orthotics. London: Mac Keith Press, 2007.

Topin N., Matecki S., Le Bris S., et al. Dose dependent effect of individualized respiratory muscle training in Duchenne muscular dystrophy. Neuromuscul. Disord.. 2002;12:576-583.

Velasco M.V., Cloin A.A., Zurakowski D., et al. Posterior spinal fusion for scoliosis in Duchenne muscular dystrophy diminishes the rate of respiratory decline. Spine. 2007;4:459-465.

Vesa J., Su H., Watts G.D., Krause S., Walter M.C., Martin B., et al. Valosin containing protein associated inclusion body myopathy: abnormal vacuolization, autophagy and cell fusion in myoblasts. Neuromuscul. Disord.. 2009;19(11):766-772. Epub 2009 Oct 13

Vignos P.J., Spencer G.E., Archibald K.C. Management of progressive muscular dystrophy in childhood. JAMA. 1963;13:89-96.

Vignos P.J., Wagner M.B., Karlinchak B., et al. Evaluation of a program for long-term treatment of Duchenne muscular dystrophy: experience at the University Hospitals of Cleveland. J. Bone Joint Surg. Am.. 1996;78(12):1844-1852.

Wagner K.R., Lechtzin N., Judge D.P. Current treatment of adult Duchenne muscular dystrophy. Biochim. Biophys. Acta. 2007;1772(2):229-237. Epub 2006 Jul 8

Wanke T., Toifl K., Merkle M., et al. Inspiratory muscle training in patients with Duchenne Muscular Dystrophy. Chest. 1994;105:475-482.

Wijmenga C., Padberg G.W., Moerer P., et al. Mapping of fascioscapulohumeral gene to chromosome 4q35-qter by multipoint linkage analysis and in situ hybridization. Genomics. 1991;9:570-575.

Webber B.A. The Brompton Hospital guide to chest physiotherapy. Oxford: Blackwell Scientific Publications, 1988.

Wiles C.M., Karni Y., Nicklin J. Laboratory testing of muscle function in the management of neuromuscular disease. J. Neurol. Neurosurg. Psychol.. 1990;53:384-387.

World Health Organization (WHO). International classification of functioning, disability and health (ICF). Geneva: World Health Organization, 2001. Online. Available: http://www.who.int/classification/icf